No Data
FDA Approves Eisai, Biogen's SBLA for Lecanemab-irmb IV Dosing
US FDA OKs Monthly Maintenance Dosing for Eisai/Biogen's Alzheimer's Drug
Express News | FDA Approves Leqembi® (Lecanemab-Irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Weekly Buzz: Last Short Week of Jan Sees Records, Trump Gives Orders
Wall Street Today: Market Pulls Back After Wild Week
Live Stock: First Week Down, Market Pulls Back a Hair After Records